Spoken Alpha
GridAI Technologies Corp.
GridAI Technologies Corp. operates two principal businesses: energy orchestration and grid optimization software for artificial intelligence data centers and large energy users through its Grid AI subsidiary, and legacy biopharmaceutical development of Adrulipase, a recombinant enzyme for treating exocrine pancreatic insufficiency.
GridAI Technologies Corp is a Healthcare company operating in Biotechnology with a $29.7M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 12, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add GRDX, reply to your welcome email and we'll prioritize it.
History
Spoken Alpha tracks GRDX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 4/10 quarters with 90% positive reaction rate
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GRDX.
$ curl https://api.spokenalpha.com/v1/companies/GRDXFAQ
Spoken Alpha indexes GRDX's earnings call transcripts at https://spokenalpha.com/companies/GRDX. Each call links to attributed speakers and parsed analyst Q&A. GridAI Technologies Corp.'s own investor relations page is at https://grid-ai.com/investors.html.
GridAI Technologies Corp. (GRDX) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | — | — | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-26 | $-0.82 | — | — | $38.2K | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $-0.73 | — | — | $36.3K | — | — | EODHD |
| Q3 FY2025 | 2025-11-27 | $-0.75 | — | — | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-0.48 | — | — | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-0.21 | — | — | $95.8K | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-7.78 | — | — | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-0.43 | $-1.16 | +62.9% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-11 | $-11.57 | — | — | — | — | — | EODHD |
| Q1 FY2024 | 2024-05-19 | $1.15 | — | — | — | — | — | EODHD |
| Q4 FY2023 | 2024-02-27 | $-8.03 | — | — | — | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-27.62 | — | — | — | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-113.18 | — | — | — | — | — | EODHD |
| Q1 FY2023 | 2023-05-21 | $-109.39 | $-0.35 | -100.0% | — | — | — | EODHD |
| Q4 FY2022 | 2023-02-28 | $-5.55 | $-58.10 | +90.5% | — | — | — | EODHD |
| Q3 FY2022 | 2022-11-22 | $2.60 | $-3.01 | +100.0% | — | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-7.50 | $-15.00 | +50.0% | — | — | — | EODHD |
| Q1 FY2022 | 2022-05-22 | $-0.66 | $-0.35 | -85.9% | — | — | — | EODHD |
| Q4 FY2021 | 2022-03-01 | $-1.53 | $-0.76 | -100.0% | — | — | — | EODHD |
| Q3 FY2021 | 2021-11-10 | $-3.27 | $-2.05 | -59.5% | — | — | — | EODHD |
Source: EODHD. GRDX reported actuals as published; sparse fields render as —.
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Missed in 2 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.23 | $1.24 | -0.5% | +2.4% | +4.7% |
| Q4 FY2026 | $1.46 | $1.42 | +2.8% | -3.0% | -2.8% |
| Q3 FY2026 | $1.42 | $1.29 | +10.2% | +4.3% | +5.2% |
| Q2 FY2026 | $1.39 | $1.47 | -5.7% | +2.4% | +4.2% |
| Q1 FY2025 | $1.44 | $1.51 | -4.5% | +3.6% | +5.9% |
CFO since 2025 • 2/4 beats (50%) • last guidance raise Q1 FY2026
| Q4 FY2025 |
| $1.47 |
| $1.37 |
| +7.2% |
| +8.2% |
| +9.6% |
| Q3 FY2025 | $1.55 | $1.57 | -1.4% | +0.1% | -1.1% |
| Q2 FY2025 | $1.38 | $1.40 | -1.3% | +0.3% | -2.3% |
| Q1 FY2024 | $1.45 | $1.54 | -5.7% | +6.4% | +4.1% |
| Q4 FY2024 | $1.56 | $1.56 | 0.0% | +2.3% | +4.3% |